December 16, 2025

Flipped Nivolumab/Ipilimumab Dosing Improves Responses, Survival, and Safety in Advanced Melanoma

The flipped dose for nivolumab 3 mg/kg and ipilimumab 1 mg/kg led to improved response rates and survival findings as well as lower severe immune-related toxicities compared with the standard dose of ...

The ASCO Post

December 15, 2025

BTX Injections Appear Safe for Refractory Digital Ischemia in Systemic Sclerosis

Botulinum toxin injections show strong safety and efficacy as an adjunctive treatment for refractory digital ischemia, ulcers, and gangrene in patients with systemic sclerosis, according to a new JAMA Dermatology meta-analysis.

Conexiant

December 11, 2025

First US Spesolimab in Pregnancy

After treatment, the patient improved rapidly, with pustules clearing within a week.

Conexiant

December 09, 2025

Top 10 States to Practice Pediatrics

These 10 states offer pediatricians the strongest mix of high earning potential, low competition, and supportive practice environments—balancing salary, demand, and quality of life for providers at any career stage.

Conexiant

December 08, 2025

Genital Lesions Reveal Age-Linked Patterns

Inflammatory conditions dominate in youth, while malignancies spike following age 60, with 35% diagnostic discordance in tertiary care cohort.

Conexiant

December 02, 2025

Fatal Neurotoxicity After Transdermal Ivermectin: What’s Your Diagnosis?

A woman in her early 40s was found unconscious after 1 month of nightly, high-dose transdermal ivermectin use for scabies, presenting with severe neurologic decline and a fatal plasma drug level—what’s your diagnosis?

Conexiant

April 01, 2018

Surgical Indications for Nonrhegmatogenous Retinal Detachment

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Retinal Physician

April 19, 2024

Dosing Proceeds in GA Study

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

New Retinal Physician

April 17, 2023

Single-Agent Pembrolizumab May Benefit Patients With Advanced Desmoplastic Melanoma

Monotherapy with pembrolizumab led to clinical responses in 89% of patients with unresectable metastatic desmoplastic melanoma, according to results from the phase II S1512 clinical trial presented by...

The ASCO Post